Prognostic model for survival in patients with metastatic renal cell carcinoma: Results from the international kidney cancer working group

Clinical Cancer Research

Volumn 17, Issue 16, 2011, Pages 5443-5450

  Manola, Judith ^a   Royston, Patrick ^h   Elson, Paul ^c   McCormack, Jennifer Bacik ^d   Mazumdar, Madhu ^g   Négrier, Sylvie ^j   Escudier, Bernard ^k   Eisen, Tim ⁱ   Dutcher, Janice ^e   Atkins, Michael ^b   Heng, Daniel Y C ^l   Choueiri, Toni K ^a   Motzer, Robert ^f   Bukowski, Ronald ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d EMMES CORPORATION   (United States)

^e ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ Cambridge Biomedical Research Centre   (United Kingdom)

^j UNIVERSITÉ DE LYON   (France)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l TOM BAKER CANCER CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; HEMOGLOBIN; INTERFERON; INTERLEUKIN 2; LACTATE DEHYDROGENASE; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DATA BASE; EXTERNAL VALIDITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNAL VALIDITY; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MONOTHERAPY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; PROGNOSTIC INDEX; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL TIME; VALIDATION STUDY;

ANTIBODIES, MONOCLONAL, HUMANIZED; BENZENESULFONATES; CARCINOMA, RENAL CELL; DATABASES, FACTUAL; FEMALE; HUMANS; INDOLES; INTERNATIONAL COOPERATION; KIDNEY NEOPLASMS; LOGISTIC MODELS; MALE; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 80051699497     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0553     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J, Ward ECancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC cancer base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr.
3. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006;98:1331-1334 (Pubitemid 44530728)
4. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48:7310-7313 (Pubitemid 19014022)
5. Palmer PA, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992;3:475-480
6. Fossa SD, Kramar A, Droz J-P. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-a. Eur J Cancer 1994;30:1310-1314 (Pubitemid 24322068)
7. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:1928-1935 (Pubitemid 30261931)
8. Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann of Oncol 2002;13:1460-1468
9. Atzpodien J, Royston P, Wandert T, Reitz M, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003;88:348-353 (Pubitemid 36308143)
10. Ma C, Bandukwala S, Burman D, Bryson J, Seccareccia D, Banerjee S, et al. Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer 2010;46:3175-3183
11. Kaplan EL, Meier. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
12. Cox DR. Regression models and life tables. J Royal Stat Soc B 1972;34:181-220.
13. Royston P, Sauerbrei W. Building multivariable regression models with continuous covariates in epidemiology-with an emphasis on fractional polynomials. Methods Inf Med 2005;44:561-571 (Pubitemid 41345381)
14. Rubin DB. Multiple Imputation for Nonresponse in Surveys. Wiley, New York: 1987.
15. Cox DR. Note on grouping. J Am Stat Assoc 1957;52:543-547
16. Pencina MJ, D'Agostino RB. Overall c as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004;23:2109-2123 (Pubitemid 38968032)
17. Royston P, Sauerbrei W. A new measure of prognostic separation in survival. Stat Med 2004;23:723-748 (Pubitemid 38279510)
18. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-5799
19. Miller ME, Hui SL. Validation techniques for logistic regression models. Stat Med 1991;10:1213-1226
20. Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011;22:295-300.
21. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. for the RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-4265